CUMBERLAND, R.I.– — Neurotech Pharmaceuticals, a biotech company focused on chronic eye diseases, has appointed Beth Marsh as Chief Commercial Officer, effective April 28. Marsh will lead the company’s commercial strategy as it prepares to launch ENCELTO™ (revakinagene taroretcel-lwey), the first and only FDA-approved treatment for idiopathic Macular Telangiectasia Type 2 (MacTel) in adults.
Marsh brings over 20 years of leadership experience in ophthalmology and retina-focused biopharma. She joins Neurotech from Apellis Pharmaceuticals, where she served as Vice President of North America Sales and Marketing in Ophthalmology, spearheading the U.S. launch of SYFOVRE, the first treatment for geographic atrophy associated with age-related macular degeneration.
“We are delighted to welcome Beth to Neurotech during this important time as we prepare for the availability of ENCELTO to patients this June,” said Richard Small, Chief Executive Officer of Neurotech. “Her expertise in launching innovative therapies and her strong relationships within the retina community will be critical as we scale our commercial efforts.”
Marsh called the opportunity to join Neurotech “transformative,” noting the historic nature of the upcoming ENCELTO launch. “Neurotech has a strong commercial foundation in place, and I look forward to working with this talented team to bring ENCELTO to patients in need,” she said.
Prior to Apellis, Marsh held leadership roles at Shire and Takeda Pharmaceuticals, where she was responsible for global commercial strategy in ophthalmology. She also served in commercial and business development roles at Aciex Therapeutics, Johnson & Johnson Vision Care, and Santen. Marsh has long been active in the ophthalmology community, previously serving as president of OWL: Advancing Diversity in Leadership.
She holds a B.S. in Business Administration with a focus on marketing from Miami University.
